| Literature DB >> 19107517 |
Heike Schützle1, Johannes Forster, Andrea Superti-Furga, Reinhard Berner.
Abstract
INTRODUCTION: Acute respiratory tract infections (ARI) in children are often treated with antibiotics even without evidence of bacterial infection. Serum procalcitonin (PCT) is elevated in bacterial but not in viral infections. PATIENTS AND METHODS: We performed a retrospective analysis of children in the PID-ARI.net study on respiratory infections to address the question of whether plasma PCT could potentially distinguish between bacterial infections requiring antibiotic therapy and viral ARI. We analysed data on 327 children who had been included in the German PID-ARI.net study and in whom nasopharyngeal aspirates had been analysed with a 19-valent multiplex reverse transcription-polymerase chain reaction-enzyme-linked immunosorbent assay for viral and atypical bacterial pathogens. Serum PCT was determined using a quantitative immunoassay (BRAHMS Kryptor PCTsensitive, Henningsdorf, Germany). We then focussed specifically on those children who were treated with antibiotics and therefore had been suspected of having bacterial infection but who had a serum PCT level lower than 0.1 ng/ml.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19107517 PMCID: PMC7086784 DOI: 10.1007/s00431-008-0899-3
Source DB: PubMed Journal: Eur J Pediatr ISSN: 0340-6199 Impact factor: 3.183
Results and diagnostic parameters for all patients and divided on the basis of PCT value (column 3 includes results of column 2 and column 4 those of column 5)
| 1 | 2 | 3 | 4 | 5 | |
|---|---|---|---|---|---|
| All patients | PCT <0.1 ng/ml | PCT <0.25 ng/ml | PCT ≥0.25 ng/ml | PCT ≥0.5 ng/ml | |
|
| 327 | 132 (40.4%) | 225 (68.8%) | 102 (31.2%) | 63 (19.3%) |
| Male/female | 189/138 | 74/58 | 132/93 | 57/45 | 31/32 |
| Positive virus testinga | 213 (65.1%) | 86 (65.2%) | 149 (66.2%) | 64 (62.7%) | 34 (54%) |
| RSV | 50 (23.5%) | 18 (20.9%) | 33 (22.1%) | 16 (25%) | 9 (26.5%) |
| Adenovirus | 42 (19.7%) | 16 (18.6%) | 27 (18.1%) | 14 (21.9%) | 9 (26.5%) |
| Rhinovirus | 112 (52.6%) | 52 (60.5%) | 84 (56.4%) | 27 (42.2%) | 14 (41.2%) |
| hMPV | 15 (7.0%) | 5 (5.8%) | 10 (6.7%) | 3 (4.7%) | 3 (8.8%) |
| Enterovirus | 27 (12.7%) | 11 (12.8%) | 20 (13.4%) | 7 (10.9%) | 5 (14.7%) |
| Parainfluenza virus 1–4 | 12 (5.6%) | 5 (5.8%) | 9 (6.0%) | 3 (4.7%) | 0 |
| Influenza virus A + B | 18 (8.5%) | 7 (8.1%) | 12 (8.1%) | 6 (9.4%) | 3 (8.8%) |
| Coronavirus | 7 (3.3%) | 3 (3.5%) | 8 (5.4%) | 2 (3.1%) | 1 (2.9%) |
| Chest radiography completed | 254 (77.7%) | 94 (71.2%) | 173 (76.5%) | 81 (79.4%) | 51 (81%) |
| Infiltrate | 124 (37.9%) | 40 (30.3%) | 74 (32.9%) | 50 (49%) | 38 (60.3%) |
| Lobar pneumonia | 54 (43.5%) | 15 (37.5%) | 30 (40.5%) | 24 (48%) | 19 (50%) |
| Bronchopneumonia | 62 (50%) | 20 (50.0%) | 38 (51.4%) | 24 (48%) | 17 (44.7%) |
| Atypical pneumonia (PCR-positive in one case) | 8 (6.5%) | 5 (12.5%) | 6 (8.1%) | 2 (4%) | 2 (5.1%) |
| CRP ≤40 mg/l | 253 (77.4%) | 119 (90.2%) | 201 (89.3%) | 52 (51%) | 26 (41.3%) |
| Median (mg/l) | 7 | 8 | 36 | 80 | |
| Mean (mg/l) | 13,5 | 15,6 | 63,6 | 83,3 | |
| Min/max (mg/l) | 3/84 | 3/133 | 3/260 | 3/260 | |
| Positive blood culture | 10 | 4 | 6 | 4 | 3 |
| | 1 | 1 | 1 | ||
| | 1 | 1 | 1 | ||
| | 1 | 1 | |||
| | 2 | 2 | 2 | ||
| | 1 | 1 | 1 | ||
| Coagulase-negative | 4 | 2 | 3 | 1 | |
| Antibiotic treatmentb | 128 (39.1%) | 38 (28.8%) | 74 (32.9%) | 54 (52.9%) | 38 (60.3%) |
| Atypical pathogen (PCR)c | 6 | 6 | 6 | – | – |
|
| 5 | 3 | 4 | 1 | 1 |
aRespiratory syncytial virus (RSV), adenovirus, enterovirus, rhinovirus, parainfluenza virus types 1–4, influenza virus A/B, human metapneumovirus (hMPV), coronavirus
bContinuation or beginning of antibiotic treatment
c Mycoplasma (M.) pneumoniae (five cases), Chlamydophila (C.) pneumoniae (one case), Legionella pneumophila (no case)
Patients with PCT <0.1 ng/ml and antibiotic treatment who were excluded, n = 20
| Patient | Reason for exclusion | Pathogen (viral/atypical) | Chest radiograph | CRP [mg/l] | PCT [ng/ml] |
|---|---|---|---|---|---|
| Male, 9 months | Antibiotic pretreatment | Rhinovirus | Normal | 83 | 0.08 |
| Female, 6 10/12 years | Antibiotic pretreatment | ∅ | Pneumonia | 37 | 0.07 |
| Female, 2 6/12 years | Antibiotic pretreatment | ∅ | Pneumonia | 14 | 0.07 |
| Male, 3 11/12 years | Antibiotic pretreatment | RSV, adenovirus, | Normal | 5 | 0.05 |
| Male, 4 1/12 years | Antibiotic pretreatment | ∅ | Normal | 42 | 0.08 |
| Male, 5 months | Cystitis | RSV | Bronchopneumonia | 19 | 0.04 |
| Female, 8 9/12 years | Sickle cell disease | ∅ | Pneumonia | 64 | 0.08 |
| Male, 3 8/12 years | Antibiotic pretreatment | Influenza A | Bronchopneumonia | 3 | 0.02 |
| Female, 10 months | Pyelonephritis | Rhinovirus | – | 27 | 0.03 |
| Male, 11 months | Former premature infant with severe chronic lung disease | Adenovirus, rhinovirus | Bronchopneumonia | 3 | 0.05 |
| Male, 2 2/12 years | Staphylodermia | ∅ | – | 7 | 0.09 |
| Male, 10 9/12 years | Antibiotic pretreatment | ∅ | Bronchopneumonia | 49 | 0.06 |
| Male, 2 months | Antibiotic pretreatment |
| – | – | 0.03 |
| Female, 8 months | Staphylodermia | Enterovirus | Normal | 3 | 0.04 |
| Female, 5 7/12 years | CHARGE syndrome | Rhinovirus | Bronchopneumonia | 29 | 0.09 |
| Female, 2 1/12 years | Congenital heart defect | Adenovirus, rhinovirus | Pneumonia | 5 | 0.04 |
| Male, 12 years | Antibiotic pretreatment |
| Atypical pneumonia | 26 | 0.08 |
| Male, 14 1/12 years | Antibiotic pretreatment |
| Normal | 3 | 0.08 |
| Male, 11 months | Antibiotic pretreatment | ∅ | Normal | 6 | 0.05 |
| Male, 15 4/12 years | Antibiotic pretreatment |
| Pneumonia | 84 | 0.07 |
| Male, 11 months | Antibiotic pretreatment | ∅ | – | 12 | 0.07 |
| Male, 3 months | Antibiotic pretreatment | Rhinovirus, | Normal | 3 | 0.06 |
| Male, 8 months | Antibiotic pretreatment | HMPV, adenovirus | Pneumonia | 3 | 0.06 |
| Female, 3 months | Aspiration pneumonia | ∅ | Normal | – | 0.09 |
| Female, 3 10/12 years | Antibiotic pretreatment | ∅ | Pneumonia | 29 | 0.08 |
| Female, 17 5/12 years | Antibiotic pretreatment | Adenovirus | Atypical pneumonia | 24 | 0.04 |
Patients with PCT <0.1 ng/ml and antibiotic treatment, n = 12 (patients treated with antibiotics prior to admission, patients with critical illnesses or children treated with antibiotics for reasons other than ARI were excluded)
| Patient | Pathogen (viral/atypical) | Chest radiograph | CRPa [mg/l] | PCT [ng/ml] | Blood culture | Antibiotic |
|---|---|---|---|---|---|---|
| Female, 1 1/12 years | ∅ | Pneumonia | 6 | 0.0 | – | Ampicillin |
| Female, 13 9/12 years | ∅ | Atypical pneumonia | 43 | 0.02 | – | Clarithromycin |
| Female, 2 1/12 years | Rhinovirus, enterovirus, coronavirus | Bronchopneumonia | 3 | 0.02 | – | Ampicillin |
| Male, 7 10/12 years | ∅ | Pneumonia | 20 | 0.05 | Positiveb | Ampicillin |
| Male, 4 6/12 years | Rhinovirus, | Atypical pneumonia | 7 | 0.06 | Negative | Erythromycin |
| Male, 7 9/12 years | Rhinovirus | Bronchopneumonia | 25 | 0.07 | – | Ampicillin |
| Female, 2 years | Rhinovirus | Pneumonia | 20 | 0.07 | – | Ampicillin |
| Female, 5 years | Rhinovirus, enterovirus | Atypical pneumonia | 34 | 0.07 | – | Erythromycin |
| Male, 6 4/12 years | Rhinovirus, | Bronchopneumonia | 8 | 0.08 | – | Erythromycin/ampicillin |
| Male, 7 months | RSV, coronavirus | Bronchopneumonia | 24 | 0.08 | – | Erythromycin |
| Female, 6 years | ∅ | Pneumonia | 5 | 0.08 | – | Erythromycin |
| Male, 4 10/12 years | ∅ | Bronchopneumonia | 6 | 0.09 | Negative | Ampicillin |
aCRP measurement at the same time as PCT measurement
bPositive for coagulase-negative staphylococci
Patients with PCT ≥0.1 and <0.25 ng/ml and antibiotic treatment, n = 20 (patients treated with antibiotics prior to admission, patients with critical illnesses, or children treated with antibiotics for reasons other than ARI were excluded)
| Patient | Pathogen (viral/atypical) | Chest radiograph | CRPa [mg/l] | PCT [ng/ml] | Blood culture | Antibiotic |
|---|---|---|---|---|---|---|
| Male, 6 11/12 years | Rhinovirus | Bronchitis | 18 | 0.1 | – | Ampicillin |
| Male 2 9/12 years | Rhinovirus | Pneumonia | 3 | 0.1 | Negative | Ampicillin |
| Male, 2 months | hMPV | Pneumonia | 8 | 0.11 | – | Cefotiam |
| Female, 4 3/12 years | Rhinovirus | Pneumonia | 25 | 0.11 | – | Ampicillin |
|
|
|
|
|
|
|
|
|
| Rhinovirus, |
|
|
| – |
|
| Male, 2 2/12 years | RSV | Bronchopneumonia | <3 | 0.13 | – | Ampicillin |
| Female, 1 month | RSV | Bronchopneumonia | <3 | 0.13 | Negative | Ceftazidime |
|
|
|
|
|
|
|
|
|
|
|
|
|
| – |
|
| Female, 6 3/12 yr | ∅ | Atypical pneumonia | 54 | 0.15 | Negative | Erythromycin |
| Male, 10 months | Rhinovirus | Bronchitis | 8 | 0.15 | Negative | Cefaclor |
| Male, 4 11/12 years | Rhinovirus | Bronchopneumonia | 16 | 0.16 | Negative | Ampicillin |
| Female, 3 3/12 years | Enterovirus | Bronchitis | 28 | 0.17 | Negative | Ampicillin |
|
|
|
|
|
| – |
|
| Female, 1 7/12 years | ∅ | Normal | 3 | 0.19 | Negative | Ampicillin |
| Male, 1 year | RSV | Bronchitis | 12 | 0.22 | Negative | Ampicillin |
| Female, 8 months | RSV, rhinovirus | Bronchopneumonia | 32 | 0.22 | – | Amoxicillin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| – |
|
In these patients (italicized rows), clinical cause and diagnostic workup gave suspicion of bacterial (super) infection
aCRP measurement at the same time as PCT measurement
bCRP 134 mg/l after approximately 44 h (no PCT measurement at the same time)
Results in patients with positive blood culture, n = 10
| Patient | Blood culture result | WBC [G/l] | CRP [mg/l] | PCT [ng/ml] | Antibiotics |
|---|---|---|---|---|---|
| Female, 5 months | CoNS | 10 | 6 | 0.3 | − |
| Male, 7 10/12 years | CoNS | 7.4 | 20 | 0.05 | + |
| Male, 3 months | CoNS | 14.4 | 3 | 0.11 | − |
| Male, 3 8/12 years | CoNS | 8.9 | 20 | 0.08 | − |
| Female, 2 5/12 years |
| 6.5 | 14 | 0.04 | − |
| Male, 1 6/12 years |
| 5.3 | 3 | 0.09 | − |
| Female, 1 5/12 years |
| 38 | 3 | 0.13 | + |
| Female, 3 2/12 years |
| 18 | 241 | 38.9 | + |
| Female, 3 1/12 years |
| 19 | 144 | 10.7 | + |
| Female, 6 months |
| 18 | 230 | 13.2 | + |
CoNS coagulase-negative Staphylococci
Laboratory data, stratified by age and gender
| 0–12 months | >12–36 months | >36 months | |||||||
|---|---|---|---|---|---|---|---|---|---|
| m | f | m | f | m | f | ||||
|
| 111 (33.9%) | 73 | 38 | 106 (32.2%) | 57 | 49 | 110 (33.4%) | 59 | 51 |
| PCT <0.1 ng/ml | 51 (45.9%) | 33 | 18 | 32 (30.1%) | 18 | 14 | 49 (44.5%) | 23 | 26 |
| PCT <0.25 ng/ml | 85 (76.6%) | 58 | 27 | 62 (58.5%) | 33 | 29 | 78 (70.9%) | 41 | 37 |
| PCT ≥0.25 ng/ml | 26 (23.4%) | 15 | 11 | 44 (41.5%) | 24 | 20 | 32 (29.1%) | 18 | 14 |
| PCT ≥0.5 ng/ml | 9 (8.1%) | 5 | 4 | 31 (29.2%) | 15 | 16 | 23 (20.9%) | 11 | 12 |
| Positive virus testing | 83 (74.8%) | 53 | 30 | 67 (63.2%) | 40 | 27 | 63 (57.3%) | 35 | 28 |
| Infiltrate | 27 (24.3%) | 17 | 10 | 42 (39.6%) | 19 | 23 | 55 (50%) | 28 | 27 |
| CRP ≤40 mg/l | 95 (85.6%) | 62 | 33 | 84 (79.2%) | 43 | 41 | 74 (67.3%) | 40 | 34 |
| Antibiotic treatment | 35 (31.5%) | 23 | 12 | 38 (35.8%) | 17 | 21 | 55 (50%) | 31 | 24 |